Claude Denham

4.2k total citations · 2 hit papers
10 papers, 3.0k citations indexed

About

Claude Denham is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Claude Denham has authored 10 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 2 papers in Neurology. Recurrent topics in Claude Denham's work include Pleural and Pulmonary Diseases (3 papers), Occupational and environmental lung diseases (3 papers) and Lung Cancer Treatments and Mutations (2 papers). Claude Denham is often cited by papers focused on Pleural and Pulmonary Diseases (3 papers), Occupational and environmental lung diseases (3 papers) and Lung Cancer Treatments and Mutations (2 papers). Claude Denham collaborates with scholars based in United States, Germany and Australia. Claude Denham's co-authors include U. Gatzemeier, Clet Niyikiza, E. Kaukel, Michael Boyer, James T. Symanowski, James J. Rusthoven, Salih Emri, Paolo Paoletti, Nicholas J. Vogelzang and Christian Manegold and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Oral and Maxillofacial Surgery and Lung Cancer.

In The Last Decade

Claude Denham

10 papers receiving 2.9k citations

Hit Papers

Phase III Study of Pemetrexed in Combination With Cisplat... 2000 2026 2008 2017 2003 2000 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
    2003 2.3k citations Nicholas J. Vogelzang, James J. Rusthoven et al. Journal of Clinical Oncology profile →
  2. Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
    2000 606 citations Alan B. Sandler, John Nemunaitis et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Claude Denham United States 7 2.6k 985 353 280 194 10 3.0k
Clet Niyikiza United States 15 3.0k 1.2× 1.4k 1.4× 585 1.7× 356 1.3× 264 1.4× 29 3.8k
Héctor Soto Parrà Italy 24 1.6k 0.6× 1.3k 1.4× 258 0.7× 137 0.5× 160 0.8× 101 2.3k
Giuseppe Roberto D’Agostino Italy 30 1.1k 0.4× 669 0.7× 231 0.7× 396 1.4× 607 3.1× 125 2.4k
Henk H. Hartgrink Netherlands 26 1.2k 0.5× 632 0.6× 466 1.3× 150 0.5× 791 4.1× 60 2.3k
James D. Reimann United States 12 813 0.3× 967 1.0× 607 1.7× 373 1.3× 209 1.1× 16 3.0k
Joo Hang Kim South Korea 27 1.9k 0.7× 1.9k 1.9× 789 2.2× 141 0.5× 326 1.7× 91 3.0k
Frank Dunphy United States 25 2.1k 0.8× 2.4k 2.4× 735 2.1× 298 1.1× 334 1.7× 65 3.6k
José Á. García-Sáenz Spain 29 1.0k 0.4× 2.1k 2.1× 631 1.8× 316 1.1× 233 1.2× 162 3.0k
José Barrueco United States 17 1.1k 0.4× 1.3k 1.4× 465 1.3× 37 0.1× 127 0.7× 36 2.0k
Purvish Parikh India 9 2.1k 0.8× 1.8k 1.8× 521 1.5× 99 0.4× 186 1.0× 21 2.6k

Countries citing papers authored by Claude Denham

Since Specialization
Citations

This map shows the geographic impact of Claude Denham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claude Denham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claude Denham more than expected).

Fields of papers citing papers by Claude Denham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claude Denham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claude Denham. The network helps show where Claude Denham may publish in the future.

Co-authorship network of co-authors of Claude Denham

This figure shows the co-authorship network connecting the top 25 collaborators of Claude Denham. A scholar is included among the top collaborators of Claude Denham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claude Denham. Claude Denham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Vogelzang, Nicholas J., James J. Rusthoven, James T. Symanowski, et al.. (2023). Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 41(12). 2125–2133. 18 indexed citations
2.
Harmon, David, et al.. (2017). Malignant Thymoma with Metastasis Associated with Paraneoplastic Myasthenia Gravis. Baylor University Medical Center Proceedings. 30(3). 330–332. 3 indexed citations
3.
Denham, Claude, et al.. (2014). Management of Central Giant Cell Granuloma With Subcutaneous Denosumab Therapy. Journal of Oral and Maxillofacial Surgery. 72(12). 2469–2484. 57 indexed citations
4.
Denham, Claude, et al.. (2013). Our Experience as a Health Volunteers Overseas–Sponsored Team in Hué, Vietnam. Baylor University Medical Center Proceedings. 26(2). 137–141. 1 indexed citations
5.
6.
Vogelzang, Nicholas J., James J. Rusthoven, James T. Symanowski, et al.. (2003). Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 21(14). 2636–2644. 2291 indexed citations breakdown →
7.
Boyer, Michael, J Jassem, James T. Symanowski, et al.. (2003). O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer. 41. S19–S19. 13 indexed citations
8.
Sandler, Alan B., John Nemunaitis, Claude Denham, et al.. (2000). Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 18(1). 122–122. 606 indexed citations breakdown →
9.
10.
Rodriguez, Gladys, Thomas D. Brown, Frank M. Balis, et al.. (1993). A phase I trial of trimetrexate (NSC352122) on a daily × 5 schedule in patients with refractory adult leukemia. Anti-Cancer Drugs. 4(2). 163–166. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clet Niyikiza Breakdown of academic impact, for papers by Héctor Soto Parrà Breakdown of academic impact, for papers by Giuseppe Roberto D’Agostino Breakdown of academic impact, for papers by Henk H. Hartgrink Breakdown of academic impact, for papers by James D. Reimann Breakdown of academic impact, for papers by Joo Hang Kim Breakdown of academic impact, for papers by Frank Dunphy Breakdown of academic impact, for papers by José Á. García-Sáenz Breakdown of academic impact, for papers by José Barrueco Breakdown of academic impact, for papers by Purvish Parikh
Rankless by CCL
2026